USA flag logo/image

An Official Website of the United States Government

Company Information:

Company Name:
COMPLEGEN, INC.
Address:
1124 COLUMBIA ST, STE 662
SEATTLE, WA 98104-2050
Phone:
(206) 447-8076
URL:
N/A
EIN:
943343600
DUNS:
N/A
Number of Employees:
N/A
Woman-Owned?:
No
Minority-Owned?:
No
HUBZone-Owned?:
No

Commercialization:

Has been acquired/merged with?:
N/A
Has had Spin-off?:
N/A
Has Had IPO?:
N/A
Year of IPO:
N/A
Has Patents?:
N/A
Number of Patents:
N/A
Total Sales to Date $:
$ 0.00
Total Investment to Date $
$ 0.00
POC Title:
N/A
POC Name:
N/A
POC Phone:
N/A
POC Email:
N/A
Narrative:
N/A

Award Totals:

Program/Phase Award Amount ($) Number of Awards
SBIR Phase I $682,570.00 3
STTR Phase I $354,754.00 1

Award List:

INDENTIFICATION OF MALE CONTRACEPTIVE LEAD COMPOUNDS

Award Year / Program / Phase:
2002 / SBIR / Phase I
Award Amount:
$98,808.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION: (provided by applicant) The long-term objective of this project is to identify lead compounds for the development of male contraceptive drugs. The project takes advantage of: 1) the observation that blocking meiotic recombination in spermatogenesis leads to… More

HIGH THROUGH-PUT DISCOVERY OF MALARIA DRUG TARGETS

Award Year / Program / Phase:
2002 / SBIR / Phase I
Award Amount:
$284,047.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (Provided by applicant): Emerging and re-emerging infectious diseases are some of the most important contributors to pain, suffering and poverty in the developing world. For parasitic diseases in general, vaccines are nonexistent and none are likely to have a… More

A Genetic System For Kinetoplastid Drug Discovery

Award Year / Program / Phase:
2003 / SBIR / Phase I
Award Amount:
$299,715.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): The goal of this project is to apply a novel, well developed cost effective means of drug target and drug discovery to parasitic disease, focusing on Trypanosoma cruzi and Leishmania, the causative agents of Chagas disease and Leishmanaisis respectively. This… More

A novel therapeutic strategy for Acute Lung Injury: Inhibition of PKC-delta

Award Year / Program / Phase:
2012 / STTR / Phase I
Award Amount:
$354,754.00
Agency:
HHS
Principal Investigator:
John T. Swindle – 206-447-8076
Research Institution:
TEMPLE UNIVERSITY
RI Contact:
Abstract:
DESCRIPTION (provided by applicant): Sepsis and the related systemic inflammatory response are the leading causes of death in intensive care units. More than 200,000 people die each year in the US from sepsis and associated complications. The lung is the organ most often affected with pulmonary… More